NewAmsterdam Pharma (NAMS) started a $300 million underwritten public offering of ordinary shares and prefunded warrants to certain investors.

Underwriters in the offering will have a 30-day option to purchase up to an additional $45 million of ordinary shares, the company said Tuesday in a statement.

"The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when" the offering may be completed or the actual size or terms, the company said.